Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Florbetaben PET scan reliably identifies beta-Amyloid in the brain

Piramal Imaging SA, a newly formed subsidiary of Piramal Healthcare Limited, announced positive first results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-Amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease.

16 Apr 2012

Two research studies on genetic components of Alzheimer's

Two research studies, co-led by UC Davis neurologist Charles DeCarli and conducted by an international team that included more than 80 scientists at 71 institutions in eight countries, has advanced understanding of the genetic components of Alzheimer's disease and of brain development. Both studies appear in the April 15 edition of the journal Nature Genetics.

16 Apr 2012

New genes may explain individual differences in brain size and intelligence

In the world's largest brain study to date, a team of more than 200 scientists from 100 institutions worldwide collaborated to map the human genes that boost or sabotage the brain's resistance to a variety of mental illnesses and Alzheimer's disease.

16 Apr 2012

Four loci appear to decrease hippocampal volume

An international team of researchers led by Boston University School of Medicine (BUSM) has identified four loci that appear to be associated with decreasing the volume of the hippocampus.

16 Apr 2012

Viewpoints: Medicare may be unintended victim of bank crisis; Health care industry's fears of law's reversal

The banks' actions led directly to an increase in government debt, which in turn has made the reduction of that debt by "cutting runaway spending" a centerpiece of the Republican presidential campaign to date.

12 Apr 2012

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

Certain antidepressants appear to decrease depression in people with Parkinson's disease without worsening motor problems, according to a study published in the April 11, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Apr 2012

AFAR to distribute nearly $2.5 million in career development awards

The American Federation for Aging Research (AFAR) announced today it will distribute nearly $2.5 million in career development awards to 83 advanced fellows and junior faculty members at 28 Hartford Centers of Excellence in Geriatric Medicine and Training.

12 Apr 2012

Number of people worldwide with dementia expected to triple by 2050; Caregivers need support, report says

The number of people living with dementia is expected to double to 65.7 million by 2030 and more than triple by 2050, with "the current estimated cost of treating and caring for those with the condition at $604 billion a year," according to a report released Wednesday by the WHO and Alzheimer's Disease International, Agence France-Presse reports.

12 Apr 2012

Preliminary results from GE Healthcare’s flutemetamol Phase 3 studies on AD

GE Healthcare today announced the preliminary results of two Phase 3 studies of its investigational PET amyloid imaging agent, [18F]flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

12 Apr 2012

Dementia burden on the Australian economy raises concerns

The report by the World Health Organization and Alzheimer's Disease International added that policy priorities should include raising awareness of the disease ensuring timely diagnosis. It estimates the global cost of dementia is more than $600 billion per year.

11 Apr 2012

Computer modeling supports theory that many dementias spread like prion diseases

A new technique for analyzing brain images offers the possibility of using magnetic resonance imaging (MRI) to predict the rate of progression and physical path of many degenerative brain diseases, report scientists at the San Francisco VA Medical Center and the University of California, San Francisco.

11 Apr 2012

Amyloid precursor protein appears to regulate its own production

A research team led by the University of South Florida Department of Psychiatry & Behavioral Neurosciences has found that a fragment of the amyloid precursor protein (APP) -- known as sAPP-α and associated with Alzheimer's disease -- appears to regulate its own production.

11 Apr 2012

Lauren Sciences, BGN Technologies sign licensing agreement for V-Smart- drug delivery technology

BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart- drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

11 Apr 2012

Siemens announces integrated imaging solution for detection of amyloid plaques

Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer's disease— in the living brain.

From Siemens Healthineers 11 Apr 2012

New report calls on nations to recognise dementia as a public health crisis

A report released today by the World Health Organization (WHO) and Alzheimer's Disease International (ADI) calls for governments and policymakers to make dementia a global public health priority.

11 Apr 2012

Reducing iron levels in blood plasma may protect brain from changes related to AD

Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

11 Apr 2012

Avid Radiopharmaceuticals receives FDA approval for Amyvid to treat AD

The U.S. Food and Drug Administration today approved Amyvid (Florbetapir F 18 Injection) a drug for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

11 Apr 2012

Two CNVs may increase risk of aggressive prostate cancer

An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer.

10 Apr 2012

Dementia sufferers and caregivers unhappy with quality of care

Dementia patients and their families have been asked to assess the quality of care available to them. Their reports are far from satisfactory. Alzheimer's Australia says dementia patients and their carers are being let down right across the health system. The Federal Government has promised to use the report to help decide how to improve the system.

9 Apr 2012

FDA approves scan to detect Alzheimer’s disease early

The test uses a chemical called florbetapir, known by the brand name Amyvid, which is a radioactive agent that tags clumps of a sticky substance called an amyloid. Amyloid proteins are hallmarks of Alzheimer's disease. The chemical, which costs $1,600 per dose, then is detected using a brain imaging technique called positron emission tomography, known as PET scans. For patients who already have some symptoms of cognitive decline, a positive scan suggests that moderate to frequent amyloid plaques are present in the brain, which is consistent with Alzheimer's disease.

9 Apr 2012

Alzheimer's Disease News and Research

Further Reading

Florbetaben PET scan reliably identifies beta-Amyloid in the brain

Two research studies on genetic components of Alzheimer's

New genes may explain individual differences in brain size and intelligence

Four loci appear to decrease hippocampal volume

Viewpoints: Medicare may be unintended victim of bank crisis; Health care industry's fears of law's reversal

Newer antidepressant decreases depression in Parkinson's patients without worsening motor problems

AFAR to distribute nearly $2.5 million in career development awards

Number of people worldwide with dementia expected to triple by 2050; Caregivers need support, report says

Preliminary results from GE Healthcare’s flutemetamol Phase 3 studies on AD

Dementia burden on the Australian economy raises concerns

Computer modeling supports theory that many dementias spread like prion diseases

Amyloid precursor protein appears to regulate its own production

Lauren Sciences, BGN Technologies sign licensing agreement for V-Smart- drug delivery technology

Siemens announces integrated imaging solution for detection of amyloid plaques

New report calls on nations to recognise dementia as a public health crisis

Reducing iron levels in blood plasma may protect brain from changes related to AD

Avid Radiopharmaceuticals receives FDA approval for Amyvid to treat AD

Two CNVs may increase risk of aggressive prostate cancer

Dementia sufferers and caregivers unhappy with quality of care

FDA approves scan to detect Alzheimer’s disease early

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News